1119 related articles for article (PubMed ID: 26708108)
21. The effects of cannabidiol (CBD) on Δ⁹-tetrahydrocannabinol (THC) self-administration in male and female Long-Evans rats.
Wakeford AGP; Wetzell BB; Pomfrey RL; Clasen MM; Taylor WW; Hempel BJ; Riley AL
Exp Clin Psychopharmacol; 2017 Aug; 25(4):242-248. PubMed ID: 28682102
[TBL] [Abstract][Full Text] [Related]
22. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans.
Chait LD; Zacny JP
Psychopharmacology (Berl); 1992; 107(2-3):255-62. PubMed ID: 1319601
[TBL] [Abstract][Full Text] [Related]
23. Marijuana's dose-dependent effects in daily marijuana smokers.
Ramesh D; Haney M; Cooper ZD
Exp Clin Psychopharmacol; 2013 Aug; 21(4):287-93. PubMed ID: 23937597
[TBL] [Abstract][Full Text] [Related]
24. Effect of oral THC pretreatment on marijuana cue-induced responses in cannabis dependent volunteers.
Lundahl LH; Greenwald MK
Drug Alcohol Depend; 2015 Apr; 149():187-93. PubMed ID: 25725933
[TBL] [Abstract][Full Text] [Related]
25. The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.
Schlienz NJ; Lee DC; Stitzer ML; Vandrey R
Drug Alcohol Depend; 2018 Jun; 187():254-260. PubMed ID: 29689485
[TBL] [Abstract][Full Text] [Related]
26. Interaction between naltrexone and oral THC in heavy marijuana smokers.
Haney M; Bisaga A; Foltin RW
Psychopharmacology (Berl); 2003 Feb; 166(1):77-85. PubMed ID: 12491025
[TBL] [Abstract][Full Text] [Related]
27. The acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.
Lawn W; Trinci K; Mokrysz C; Borissova A; Ofori S; Petrilli K; Bloomfield M; Haniff ZR; Hall D; Fernandez-Vinson N; Wang S; Englund A; Chesney E; Wall MB; Freeman TP; Curran HV
Addiction; 2023 Jul; 118(7):1282-1294. PubMed ID: 36750134
[TBL] [Abstract][Full Text] [Related]
28. Effects of cannabidiol in cannabis flower: Implications for harm reduction.
Gibson LP; Karoly HC; Ellingson JM; Klawitter J; Sempio C; Squeri JE; Bryan AD; Bidwell LC; Hutchison KE
Addict Biol; 2022 Jan; 27(1):e13092. PubMed ID: 34467598
[TBL] [Abstract][Full Text] [Related]
29. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
[TBL] [Abstract][Full Text] [Related]
30. Subjective and physiological effects after controlled Sativex and oral THC administration.
Karschner EL; Darwin WD; McMahon RP; Liu F; Wright S; Goodwin RS; Huestis MA
Clin Pharmacol Ther; 2011 Mar; 89(3):400-7. PubMed ID: 21289620
[TBL] [Abstract][Full Text] [Related]
31. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.
Haney M; Ramesh D; Glass A; Pavlicova M; Bedi G; Cooper ZD
Neuropsychopharmacology; 2015 Oct; 40(11):2489-98. PubMed ID: 25881117
[TBL] [Abstract][Full Text] [Related]
32. The acute effects of cannabis, with and without cannabidiol, on attentional bias to cannabis related cues: a randomised, double-blind, placebo-controlled, cross-over study.
Hall D; Lawn W; Ofori S; Trinci K; Borissova A; Mokrysz C; Petrilli K; Bloomfield MAP; Wall MB; Freeman TP; Curran HV
Psychopharmacology (Berl); 2024 Jun; 241(6):1125-1134. PubMed ID: 38416223
[TBL] [Abstract][Full Text] [Related]
33. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
[TBL] [Abstract][Full Text] [Related]
34. Oral fluid cannabinoids in chronic cannabis smokers during oral δ9-tetrahydrocannabinol therapy and smoked cannabis challenge.
Lee D; Vandrey R; Mendu DR; Anizan S; Milman G; Murray JA; Barnes AJ; Huestis MA
Clin Chem; 2013 Dec; 59(12):1770-9. PubMed ID: 23938457
[TBL] [Abstract][Full Text] [Related]
35. Changing landscape of cannabis: novel products, formulations, and methods of administration.
Spindle TR; Bonn-Miller MO; Vandrey R
Curr Opin Psychol; 2019 Dec; 30():98-102. PubMed ID: 31071592
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.
Bergeria CL; Spindle TR; Cone EJ; Sholler D; Goffi E; Mitchell JM; Winecker RE; Bigelow GE; Flegel R; Vandrey R
J Anal Toxicol; 2022 Jul; 46(6):583-591. PubMed ID: 35438179
[TBL] [Abstract][Full Text] [Related]
37. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
38. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
[TBL] [Abstract][Full Text] [Related]
39. Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults.
Matheson J; Sproule B; Di Ciano P; Fares A; Le Foll B; Mann RE; Brands B
Psychopharmacology (Berl); 2020 Feb; 237(2):305-316. PubMed ID: 31637452
[TBL] [Abstract][Full Text] [Related]
40. Influence of tiagabine maintenance on cannabis effects and related behaviors in daily cannabis users.
Wesley MJ; Westgate PM; Stoops WW; Kelly TH; Hays LR; Lile JA
Exp Clin Psychopharmacol; 2018 Jun; 26(3):310-319. PubMed ID: 29863387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
